Dybly Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Angel

  • Latest Deal Amount
  • $134K

  • Investors
  • 2

Dybly General Information

Description

Operator of a pharmaceutical company intended for inflammatory and fibrotic disease patients. The company manufactures several molecules with activity and safety profiles backed by hypothesis-driven small molecule drug design with validation by empirical data, enabling patients with fibrotic diseases, blood cancer, and rheumatoid arthritis to get a better cure.

Contact Information

Website
www.dybly.com
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Corporate Office
  • Im Erasmushaus
  • Baeumleingasse 18
  • 4051 Basel
  • Switzerland
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Im Erasmushaus
  • Baeumleingasse 18
  • 4051 Basel
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dybly Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 21-Oct-2020 $134K Completed Generating Revenue
2. Angel (individual) 25-Feb-2008 Completed Startup
1. Angel (individual) 01-Dec-2006 Completed Startup
To view Dybly’s complete valuation and funding history, request access »

Dybly Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 19,444 $0.119843 $16.81 $16.81 1x $16.81 1.19%
To view Dybly’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Dybly Patents

  • 2

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Dybly Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20090004121-A1 Combination of picotamide with nafronyl Inactive 28-Jun-2007
US-20080293772-A1 Salts of picotamide Inactive 21-May-2007

Dybly Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioBac Angel Group Minority
Eva Capital Accelerator/Incubator Minority
To view Dybly’s complete investors history, request access »

Ready to get started?

Request a free trial

Dybly FAQs

  • When was Dybly founded?

    Dybly was founded in 2006.

  • Where is Dybly headquartered?

    Dybly is headquartered in Basel, Switzerland.

  • What industry is Dybly in?

    Dybly’s primary industry is Pharmaceuticals.

  • Is Dybly a private or public company?

    Dybly is a Private company.

  • What is the current valuation of Dybly?

    The current valuation of Dybly is .

  • What is Dybly’s current revenue?

    The current revenue for Dybly is .

  • How much funding has Dybly raised over time?

    Dybly has raised $644K.

  • Who are Dybly’s investors?

    BioBac and Eva Capital have invested in Dybly.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »